The lack of intestinal and hepatic steatosis in the c655 mutant fish suggests that an MTP inhibitor that selectively targets TG transfer activity could potentially lower plasma lipids while preventing gastrointestinal and liver side effects. Here, MTTP is linked to Hepatic steatosis.